EXPRS2 — ExpreS2ion Biotech Holding AB Share News
0.000.00%
Last trade - 00:00- SEK24.46m
- -SEK8.46m
- SEK12.21m
Brief: Expres2ion Q3 Loss After Financial Items Widens To SEK 31.8 Mln
Brief: ExpreS2ion Biotech Says First Subject Vaccinated In COVID-19 Phase 3 Clinical Trial For ABNcoV2 As A Booster Vaccine
Brief: Expres2ion Q2 Loss For Period Widens To SEK 25.5 Million
Brief: Expres2ion Biotech Holding Q1 Loss Widens To SEK 14.8 Mln
Brief: ExpreS2ion Biotech Announces Additional Positive Preclinical Proof-Of-Concept Results For The HER2-cVLP Breast Cancer Vaccine
Brief: Expres2ion Announces Final Outcome Of Fully Guaranteed Rights Issue
Brief: Expres2ion Announces Fully Guaranteed Rights Issue Of About SEK 73 Million
Brief: Expres2ion Q4 Loss For Period Narrows To SEK 14.3 Mln
Brief: Expres2ion Biotech Holding Provides Update On Its Novel Breast Cancer Vaccine Candidate Es2b-C001
Brief: ExpreS2ion Announces Further Preclinical Proof-Of-Concept Results For HER2-cVLP Breast Cancer Vaccine
Brief: Expres2ion Announces Topline Results For Its Breast Cancer Vaccine
Brief: ExpreS2ion Biotech Holding AB Says Positive Topline Results Reported For Phase II Covid-19 Clinical Trial With ABNCoV2 Vaccine
Brief: Expres2ion Q3 Pre-Tax Loss Widens To SEK 10.3 Million
Brief: Expres2ion Biotech Announces Positive Results From Covid-19 Study With Abncov2
Brief: ExpreS2ion Warrants Of Series To5 Were Subscribed To Approximately 97.4 %
Brief: Expres2ion Biotech Q2 Pre-Tax Loss Widens To SEK 10.1 Mln
Brief: Expres2ion Q2 Pre-Tax Loss Widens To SEK 10.1 Mln
Bavarian Nordic jumps on positive COVID-19 vaccine trial results
Brief: ExpreS2ion Biotech: Positive Safety And Efficacy Outcome Of Covid-19 Clinical Phase I/II Study For The ABNCoV2 Vaccine